10 Questions About 4-Aminopyridine and the Treatment of Multiple Sclerosis

被引：1
|
作者：
Bever, Christopher T., Jr. [1 ,2 ]
机构：
[1] Univ Maryland, Sch Med, UMH, Dept Neurol, Baltimore, MD 21201 USA
[2] VA Multiple Selerosis Ctr Excellence E, VA Maryland Healthcare Syst, Res & Neurol Serv, Baltimore, MD USA
来源：
NEUROLOGIST | 2009年 / 15卷 / 03期
关键词：
MAMMALIAN NERVE-FIBERS; DOUBLE-BLIND; SYMPTOMATIC TREATMENT; CLINICAL SIGNS;
D O I：
10.1097/NRL.0b013e3181679be5
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：161 / 162
页数：2
相关论文
共 50 条
  • [1] Enhancing Neural Transmission in Multiple Sclerosis (4-Aminopyridine Therapy)
    Goodman, Andrew D.
    Stone, Robert Thompson
    NEUROTHERAPEUTICS, 2013, 10 (01) : 106 - 110
  • [2] 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
    Jensen, Henrik Boye
    Ravnborg, Mads
    Dalgas, Ulrik
    Stenager, Egon
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2014, 7 (02) : 97 - 113
  • [3] 4-Aminopyridine (Fampridine) : A new attempt for the symptomatic treatment of multiple sclerosis
    Husseini L.
    Leussink V.I.
    Kieseier B.C.
    Hartung H.-P.
    Der Nervenarzt, 2010, 81 (2) : 203 - 211
  • [4] 4-Aminopyridine (Fampridine)
    Husseini, L.
    Leussink, V. I.
    Kieseier, B. C.
    Hartung, H. -P.
    NERVENARZT, 2010, 81 (02): : 203 - 211
  • [5] 4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis
    Goebel, Kerstin
    Wedell, Jan-Hendrik
    Herrmann, Alexander M.
    Wachsmuth, Lydia
    Pankratz, Susann
    Bittner, Stefan
    Budde, Thomas
    Kleinschnitz, Christoph
    Faber, Cornelius
    Wiendl, Heinz
    Meuth, Sven G.
    EXPERIMENTAL NEUROLOGY, 2013, 248 : 62 - 71
  • [6] Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis
    Dietrich, Michael
    Koska, Valeria
    Hecker, Christina
    Goettle, Peter
    Hilla, Alexander M.
    Heskamp, Annemarie
    Lepka, Klaudia
    Issberner, Andrea
    Hallenberger, Angelika
    Baksmeier, Christine
    Steckel, Julia
    Balk, Lisanne
    Knier, Benjamin
    Korn, Thomas
    Havla, Joachim
    Martinez-Lapiscina, Elena H.
    Sola-Valls, Nuria
    Manogaran, Praveena
    Olbert, Elisabeth D.
    Schippling, Sven
    Cruz-Herranz, Andres
    Yiu, Hao
    Button, Julia
    Caldito, Natalia Gonzalez
    von Gall, Charlotte
    Mausberg, Anne K.
    Stettner, Mark
    Zimmermann, Hannah G.
    Pau, Friedemann
    Brandt, Alexander U.
    Kuery, Patrick
    Goebels, Norbert
    Aktas, Orhan
    Berndt, Carsten
    Saidha, Shiv
    Green, Ari J.
    Calabresi, Peter A.
    Fischer, Dietmar
    Hartung, Hans-Peter
    Albrecht, Philipp
    BRAIN, 2020, 143 : 1127 - 1142
  • [7] Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy
    Horton, Lindsay
    Conger, Amy
    Conger, Darrel
    Remington, Gina
    Frohman, Teresa
    Frohman, Elliot
    Greenberg, Benjamin
    NEUROLOGY, 2013, 80 (20) : 1862 - 1866
  • [8] Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond
    Leussink, Verena Isabell
    Montalban, Xavier
    Hartung, Hans-Peter
    CNS DRUGS, 2018, 32 (07) : 637 - 651
  • [9] Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)
    Keune, Philipp M.
    Cocks, Adam J.
    Young, William R.
    Burschka, Janina M.
    Hansen, Sascha
    Hofstadt-van Oy, Ulrich
    Oschmann, Patrick
    Muenssinger, Jana
    BMC NEUROLOGY, 2015, 15
  • [10] Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine
    Boiko, Nina
    Kucher, Volodymyr
    Eaton, Benjamin A.
    Stockand, James D.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (13) : 9418 - 9427
12345